Akebia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2018--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences:The 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 12:30 p.m. Eastern Time at the Lotte New York Palace Hotel. Akebia will participate in a fireside chat discussion; and The Global Mizuho Investor Conference on Monday, December 3, 2018, at the Lotte New York Palace Hotel.
A replay of the webcast from the Piper Jaffray Healthcare Conference will be available on the company’s website at www.akebia.com the day following the conference. To access, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005661/en/
CONTACT: John Garabo
Director, Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Akebia Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 11/20/2018 04:05 PM/DISC: 11/20/2018 04:05 PM